Cargando…

LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels

Lipoprotein(a) [Lp(a)] levels are an independent risk factor for coronary artery disease (CAD). Two single-nucleotide polymorphisms (rs10455872, rs3798220) and number of KIV-2 repeats in the gene encoding Lp(a) (LPA) are associated with Lp(a) and CAD. Our aim was to investigate whether in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rehberger Likozar, Andreja, Blinc, Aleš, Trebušak Podkrajšek, Katarina, Šebeštjen, Miran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707421/ https://www.ncbi.nlm.nih.gov/pubmed/34940537 http://dx.doi.org/10.3390/jcdd8120181

Ejemplares similares

The Influence of Treatment with PCSK9 Inhibitors and Variants in the CRP (rs1800947), TNFA (rs1800629), and IL6 (rs1800795) Genes on the Corresponding Inflammatory Markers in Patients with Very High Lipoprotein(a) Levels
por: Levstek, Tina, et al.
Publicado: (2022)

Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels
por: Rehberger Likozar, Andreja, et al.
Publicado: (2022)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors
por: Likozar, Andreja Rehberger, et al.
Publicado: (2023)

Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors
por: Hrovat, Katja, et al.
Publicado: (2022)

Influence of lipid-lowering drugs on inflammation: what is yet to be done?
por: Ugovšek, Sabina, et al.
Publicado: (2021)

Atherosclerotic Cardiovascular Disease: Risk Assessment, Prevention and Treatment Strategies
por: Jeras, Jernej, et al.
Publicado: (2022)

Lipoprotein(a)—The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation
por: Ugovšek, Sabina, et al.
Publicado: (2021)

TNF-α Predicts Endothelial Function and Number of CD34(+) Cells after Stimulation with G-CSF in Patients with Advanced Heart Failure
por: Ugovšek, Sabina, et al.
Publicado: (2022)

Haplotype Analysis of PPARγ Gene Polymorphisms and the Lipoprotein (a) Level
por: SHEN, Chao, et al.
Publicado: (2018)

Accuracy of low-density lipoprotein cholesterol estimation at very low levels
por: Quispe, Renato, et al.
Publicado: (2017)

Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy
por: Levstek, Tina, et al.
Publicado: (2023)

Elevated lipoprotein(a) and genetic polymorphisms in the LPA gene may predict cardiovascular events
por: Gu, Jun-Xu, et al.
Publicado: (2022)

Lipoprotein Lipase and PPAR Alpha Gene Polymorphisms, Increased Very-Low-Density Lipoprotein Levels, and Decreased High-Density Lipoprotein Levels as Risk Markers for the Development of Visceral Leishmaniasis by Leishmania infantum
por: Carvalho, Márcia Dias Teixeira, et al.
Publicado: (2014)

The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A
por: Grüneis, Rebecca, et al.
Publicado: (2022)

The Association of Syntax Score with Levels of Lipoprotein(a) and Inflammatory Biomarkers in Patients with Stable Coronary Artery Disease and Different Low-Density Lipoprotein Cholesterol Levels
por: Xu, Weifeng, et al.
Publicado: (2020)

Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene
por: Coassin, Stefan, et al.
Publicado: (2022)

Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a)
por: Krychtiuk, Konstantin A., et al.
Publicado: (2015)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

The association of very-low-density lipoprotein with ankle-brachial index in peritoneal dialysis patients with controlled serum low-density lipoprotein cholesterol level
por: Kanda, Eiichiro, et al.
Publicado: (2013)

The rs10455872-G allele of the LPA gene is associated with high lipoprotein(a) levels and increased aortic valve calcium in a Mexican adult population
por: Cardoso-Saldaña, Guillermo, et al.
Publicado: (2019)

An Intron c.103-3T>C Variant of the AMELX Gene Causes Combined Hypomineralized and Hypoplastic Type of Amelogenesis Imperfecta: Case Series and Review of the Literature
por: Leban, Tina, et al.
Publicado: (2022)

Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease
por: Kimak, Elżbieta, et al.
Publicado: (2018)

Telomere Attrition in Chronic Kidney Diseases
por: Levstek, Tina, et al.
Publicado: (2023)

Special Issue “Genetics and Epigenetics in Endocrine Disorders”
por: Trebušak Podkrajšek, Katarina, et al.
Publicado: (2023)

Hemoglobin level and lipoprotein particle size
por: Hämäläinen, Päivi, et al.
Publicado: (2018)

Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease
por: Trinder, Mark, et al.
Publicado: (2020)

Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
por: Schachtl-Riess, Johanna F., et al.
Publicado: (2021)

Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
por: Xu, Rui-Xia, et al.
Publicado: (2014)

Elevated lipoprotein (a) levels are associated with the acute myocardial infarction in patients with normal low-density lipoprotein cholesterol levels
por: Cai, Gaojun, et al.
Publicado: (2019)

Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein
Publicado: (1982)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans
por: Bagdade, John D., et al.
Publicado: (2018)

Nigerian propolis improves blood glucose, glycated hemoglobin A1c, very low-density lipoprotein, and high-density lipoprotein levels in rat models of diabetes
por: Oladayo, Mustafa Ibrahim
Publicado: (2016)

The associations between p,p’-DDE levels and plasma levels of lipoproteins and their subclasses in an elderly population determined by analysis of lipoprotein content
por: Jugan, Juliann, et al.
Publicado: (2020)

Biomarkers of Fabry Nephropathy: Review and Future Perspective
por: Levstek, Tina, et al.
Publicado: (2020)

Duration of Type 2 Diabetes and Very Low Density Lipoprotein Levels Are Associated with Cognitive Dysfunction in Metabolic Syndrome
por: Yogi-Morren, Divya, et al.
Publicado: (2014)

Reduced Serum Levels of Triglyceride, Very Low Density Lipoprotein Cholesterol and Apolipoprotein B in Parkinson’s Disease Patients
por: Wei, Qiang, et al.
Publicado: (2013)

Elevated free testosterone levels and reduced very low-density lipoprotein levels in men with lifelong premature ejaculation: a preliminary study
por: Zhao, Jun, et al.
Publicado: (2021)

The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins
por: Chrostek, Lech, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ct1no4272afedj07rhv2v2oho0